諾華藥廠NVS
紐約證券 · USD
113.74
-2.89
(-2.48%)
收盤 08/01 03:59 (UTC+8)
盤後
113.80
+0.06
(+0.05%)
08/01 03:59 (UTC+8)
諾華藥廠NVS
113.74
-2.89
(-2.48%)
財務數據
損益表
- 110.47
- 117.45
- 120.92
- 117.76
- 121.20
- 128.72
- 131.72
- 135.58
- 136.20
- 148.36
- -15.59
- 6.32
- 2.95
- -2.61
- 2.92
- 6.20
- 2.33
- 2.93
- 0.46
- 8.93
- 營業收入(億)
- 季增長率(%)
單位：美元千元
2025/Q2 | 2025/Q1 | 2024/Q4 | 2024/Q3 | 2024/Q2 | 2024/Q1 | 2023/Q4 | 2023/Q3 | 2023/Q2 | 2023/Q1 | |
營業收入淨額 | 14,836,000 | 13,620,000 | 13,558,000 | 13,172,000 | 12,872,000 | 12,120,000 | 11,776,000 | 12,092,000 | 11,745,000 | 11,047,000 |
營業成本 | 3,322,000 | 3,227,000 | 3,324,000 | 3,234,000 | 3,173,000 | 3,096,000 | 3,022,000 | 3,117,000 | 3,342,000 | 2,991,000 |
營業毛利 | 11,514,000 | 10,393,000 | 10,234,000 | 9,938,000 | 9,699,000 | 9,024,000 | 8,754,000 | 8,975,000 | 8,403,000 | 8,056,000 |
營業費用 | 6,650,000 | 5,730,000 | 6,704,000 | 6,311,000 | 5,685,000 | 5,651,000 | 6,172,000 | 7,213,000 | 5,596,000 | 5,438,000 |
研發費用 | 2,727,000 | 2,366,000 | 2,842,000 | 2,392,000 | 2,367,000 | 2,421,000 | 2,567,000 | 3,925,000 | 2,304,000 | 2,575,000 |
推銷及管理費用 | 3,442,000 | 3,058,000 | 3,501,000 | 3,134,000 | 3,091,000 | 2,840,000 | 3,444,000 | 3,091,000 | 3,091,000 | 2,891,000 |
非經常性項目費用 | - | - | - | - | - | - | - | - | - | - |
其他營業費用 | 481,000 | 306,000 | 361,000 | 785,000 | 227,000 | 390,000 | 161,000 | 197,000 | 201,000 | -28,000 |
營業利益 | 4,864,000 | 4,663,000 | 3,530,000 | 3,627,000 | 4,014,000 | 3,373,000 | 2,582,000 | 1,762,000 | 2,807,000 | 2,618,000 |
其他收入及費用 | - | - | - | - | - | - | - | - | - | - |
利息費用 | 289,000 | 270,000 | 275,000 | 264,000 | 246,000 | 221,000 | 217,000 | 222,000 | 216,000 | 200,000 |
稅前純益 | 4,531,000 | 4,407,000 | 3,285,000 | 3,385,000 | 3,841,000 | 3,129,000 | 2,377,000 | 1,552,000 | 2,674,000 | 2,520,000 |
所得稅 | 507,000 | 798,000 | 465,000 | 200,000 | 595,000 | 441,000 | -261,000 | 39,000 | 403,000 | 370,000 |
稅後純益 | 4,041,000 | 3,606,000 | 2,818,000 | 3,189,000 | 3,246,000 | 2,688,000 | 8,480,000 | 1,761,000 | 2,316,000 | 2,293,000 |
基本每股稅後盈餘(元) | 2.07 | 1.83 | 1.42 | 1.58 | 1.60 | 1.31 | 4.14 | 0.85 | 1.11 | 1.09 |
稀釋每股稅後盈餘(元) | 2.06 | 1.82 | 1.41 | 1.57 | 1.59 | 1.31 | 4.11 | 0.85 | 1.11 | 1.08 |
基本平均股數(千股) | 1948000.00 | 1968000.00 | 1987000.00 | 2012000.00 | 2033000.00 | 2044000.00 | 2050000.00 | 2062000.00 | 2083000.00 | 2110000.00 |
稀釋平均股數(千股) | 1960000.00 | 1979000.00 | 2004000.00 | 2027000.00 | 2046000.00 | 2056000.00 | 2065000.00 | 2075000.00 | 2095000.00 | 2120000.00 |
還原基本每股稅後盈餘(元) | 2.07 | 1.83 | 1.42 | 1.58 | 1.60 | 1.31 | 4.14 | 0.85 | 1.11 | 1.09 |
還原稀釋每股稅後盈餘(元) | 2.06 | 1.82 | 1.41 | 1.57 | 1.59 | 1.31 | 4.11 | 0.85 | 1.11 | 1.08 |
還原基本平均股數(千股) | 1,948,000 | 1,968,000 | 1,987,000 | 2,012,000 | 2,033,000 | 2,044,000 | 2,050,000 | 2,062,000 | 2,083,000 | 2,110,000 |
還原稀釋平均股數(千股) | 1,960,000 | 1,979,000 | 2,004,000 | 2,027,000 | 2,046,000 | 2,056,000 | 2,065,000 | 2,075,000 | 2,095,000 | 2,120,000 |
EBITDA(千元) | 6,093,000 | 5,828,000 | 5,186,000 | 5,618,000 | 5,249,000 | 4,664,000 | 10,024,000 | 5,133,000 | 4,643,000 | 4,733,000 |